These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28431263)

  • 21. Epigenetic tools in potential anticancer therapy.
    Sebova K; Fridrichova I
    Anticancer Drugs; 2010 Jul; 21(6):565-77. PubMed ID: 20436342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.
    Berndsen RH; Abdul UK; Weiss A; Zoetemelk M; Te Winkel MT; Dyson PJ; Griffioen AW; Nowak-Sliwinska P
    Angiogenesis; 2017 May; 20(2):245-267. PubMed ID: 28378227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
    Dueñas-Gonzalez A; Coronel J; Cetina L; González-Fierro A; Chavez-Blanco A; Taja-Chayeb L
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1433-44. PubMed ID: 25154405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining epigenetic and cytotoxic therapy in the treatment of solid tumors.
    Plimack ER; Stewart DJ; Issa JP
    J Clin Oncol; 2007 Oct; 25(29):4519-21. PubMed ID: 17925545
    [No Abstract]   [Full Text] [Related]  

  • 25. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.
    Vendetti FP; Rudin CM
    Expert Opin Biol Ther; 2013 Sep; 13(9):1273-85. PubMed ID: 23859704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer.
    Mohammad HP; Barbash O; Creasy CL
    Nat Med; 2019 Mar; 25(3):403-418. PubMed ID: 30842676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.
    Zahnow CA; Topper M; Stone M; Murray-Stewart T; Li H; Baylin SB; Casero RA
    Adv Cancer Res; 2016; 130():55-111. PubMed ID: 27037751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment.
    Shirbhate E; Singh V; Jahoriya V; Mishra A; Veerasamy R; Tiwari AK; Rajak H
    Eur J Med Chem; 2024 Jan; 263():115938. PubMed ID: 37989059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting epigenetics for the treatment of prostate cancer: recent progress and future directions.
    Lin J; Wang C; Kelly WK
    Semin Oncol; 2013 Jun; 40(3):393-401. PubMed ID: 23806502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular targets for epigenetic therapy of cancer.
    Humeniuk R; Mishra PJ; Bertino JR; Banerjee D
    Curr Pharm Biotechnol; 2009 Feb; 10(2):161-5. PubMed ID: 19199948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic cancer therapy: rationales, targets and drugs.
    Rius M; Lyko F
    Oncogene; 2012 Sep; 31(39):4257-65. PubMed ID: 22179827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylases and epigenetic therapies of hematological malignancies.
    Mercurio C; Minucci S; Pelicci PG
    Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer epigenetics: current and evolving treatment.
    Purja S; Nguyen DT; Kim E
    Breast Cancer; 2024 Sep; 31(5):869-885. PubMed ID: 38861041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual targeting of epigenetic therapy in cancer.
    Hellebrekers DM; Griffioen AW; van Engeland M
    Biochim Biophys Acta; 2007 Jan; 1775(1):76-91. PubMed ID: 16930846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenomes as therapeutic targets.
    Hamm CA; Costa FF
    Pharmacol Ther; 2015 Jul; 151():72-86. PubMed ID: 25797698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic modulation of resistance to chemotherapy?
    Brown R; Glasspool R
    Ann Oncol; 2007 Sep; 18(9):1429-30. PubMed ID: 17761701
    [No Abstract]   [Full Text] [Related]  

  • 37. Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives.
    Schiffmann I; Greve G; Jung M; Lübbert M
    Epigenetics; 2016 Dec; 11(12):858-870. PubMed ID: 27846368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
    Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Epigenetic therapy for hematologic malignancies].
    Kobayashi Y
    Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
    Conley BA; Wright JJ; Kummar S
    Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.